



## FOR IMMEDIATE RELEASE

### **“Xeris Pharmaceuticals Appoints Dr. Yash Sabharwal as Chief Operating Officer”**

*Austin, Texas – June 15, 2010* - Xeris Pharmaceuticals (“Xeris”) announced today that Yash Sabharwal, Ph.D. has joined the Company as its Chief Operating Officer. As Chief Operating Officer (COO), Dr. Sabharwal will be responsible for execution of Xeris’ strategic plan and management of its day-to-day operations.

“We are very excited to begin the development of the Xeris management team with the recruitment of Yash as COO,” stated John Kinzell, Ph.D., CEO of Xeris. “He brings a critical skill set focused on the financing and infrastructure development of early-stage technology companies. He will be a tremendous asset as we seek additional funding and continue the development of our lead product.”

“Xeris has developed some powerful technology around the formulation of biologics that will significantly improve the patient experience and have a major impact on the rising cost of health care around the world,” said Dr. Sabharwal. “I am excited to be a part of the team that will bring innovative health care products developed with this technology to market.”

Prior to joining Xeris, Dr. Sabharwal co-founded Optical Insights, LLC which developed and commercialized imaging platforms for fluorescence microscopy, high-throughput screening (HTS), and high-content screening (HCS). He led various business development efforts for Optical Insights with an emphasis on financial operations as CFO from early stage inception to the sale of the company in 2005 to Roper Industries. Since 2006, he has worked with various entrepreneurial organizations providing expertise in the areas of product and business development. Dr. Sabharwal has a B.S. in Optics from the University of Rochester and a M.S. and Ph.D. in Optical Sciences from the University of Arizona.

#### **About Xeris**

Xeris develops patient-friendly injectables based on its XeriJect™ and XeriSol™ formulation and delivery platforms. The company’s products are ultra-low-volume, injectable bio-pharmaceuticals packaged in an auto-injector pen that patients and their caregivers can use at home or work. Bio-pharmaceuticals are the fastest growing category of therapeutics and are forecasted to be 6 of the top 10 drugs by 2014. The current paradigm of delivery requires nearly all of these drugs to be administered by injection or infusion, often in a clinical setting, decreasing compliance, increasing cost and providing a terrible patient experience. Xeris aspires to change this paradigm by developing ultra-low volume, ready-to-use bio-pharmaceuticals delivered through patient-friendly injectable devices, many of which would be self-administered in the comfort of the patient’s home. Products built on Xeris’ technologies would simplify administration and ease the pain of injections, improving the experience for hundreds of millions of patients. For more information, visit [www.xerispharma.com](http://www.xerispharma.com).

SOURCE - Xeris Pharmaceuticals, Inc.

###